Skip to content

Axogen AXGN Additional Paid-In Capital

Additional Paid-In Capital at other companies

Baxter International logo
Baxter InternationalBAX
$6.21B-1.5%
IAR
Integra LifeSciencesIART
$1.34B+1.3%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$233.45M+7.5%
Enovis logo
EnovisENOV
$3.06B+1.2%
Medtronic logo
MedtronicMDT
$20.93B+0.4%

Other financials

Income statement

See full
Revenue$61.5M+26.6%
Gross profit$46.2M+32.2%
Operating income-$2.8M-70.5%
Net income-$19.6M-411%
EPS (diluted)-$0.38-375%

Balance sheet

See full
Cash & equivalents$84.7M+251%
Total debt$20.6M-69.8%
Total equity$244.8M+132%
Total assets$289.5M+47.6%

Cash flow

See full
Operating cash flow$1.6M+112%
CapEx$2.8M+989%
Free cash flow-$1.2M+90.9%

Valuation

See full
Market cap$2.26B+110%
Enterprise value$2.2B+91.4%
P/S9.5×+4.0×

Profitability

See full
Gross margin75%+0.8pp
Operating margin-3.8%
Net margin-13.2%-22.8pp
FCF margin-12.9%-3.8pp

Returns & leverage

See full
Return on equity-18%-70.5pp
Debt / equity0.1×-0.6×
Current ratio7.1×+2.8×

Where this comes from

Reported directly by Axogen in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Axogen’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axogen's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axogen's additional paid-in capital?
Axogen (AXGN) reported additional paid-in capital of $570.82M in Q1 2026.
How has Axogen's additional paid-in capital changed year-over-year?
Axogen's additional paid-in capital increased by 42.7% year-over-year, from $400M to $570.82M.
What is the long-term trend for Axogen's additional paid-in capital?
Over 5 years (2020 to 2025), Axogen's additional paid-in capital has grown at a 5.9% compound annual growth rate (CAGR), from $326.39M to $435.34M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.